01
Baseline bloodwork
We test three proprietary biomarkers to understand cancer cell proliferation risk and metabolic load.
Dubai Translational Initiative
Nasrinova Biogentics slows cancer cell activity through precision sugar-control.
Founded by Saeed Ghods, Nasrinova delivers a clinically supervised metabolic reset: benchmark the biomarkers, install continuous glucose monitoring, then coach each patient through a 30-day sugar reduction sprint.
Live Glucose Feed
86 mg/dL
Stable
Biomarker Score
63 → 41
Post 30-Day Sugar Reduction
Three-step protocol
Data-driven metabolic intervention
Each patient receives a personalized view of their glucose exposure and immune response, then learns to drive down daily sugar load with hands-on coaching.
02
Phone-connected glucometer
A discreet, always-on sensor streams glucose data to the patient and clinical team in real time.
03
30-day reduction sprint
Guided by nutritionists, patients lower sugar intake and watch their biomarkers shift after 30 days.
Continuous monitoring
Live glucose dashboard + proactive alerts
- Adaptive targets tuned to each patient’s baseline.
- Daily coaching prompts based on glycemic variability.
- Secure data shares with oncologists in Dubai hospitals.
Today’s exposure
LowMeasurable change
Biomarkers respond within 30 days
Our pilot in Dubai shows a consistent decline in inflammatory markers when patients maintain low sugar intake.
-34%
Average reduction in proliferative biomarker
3x
Increase in patient awareness of triggers
2 weeks
Time to stabilize glucose variability
Dubai-backed rollout
Partner with us
Nasrinova Biogentics is seeking Dubai hospital systems and sovereign health funds to scale patient access. Prospective patients begin with a simple application and concierge onboarding.